Record-high sales and EBITA were achieved, driven by strong organic growth, robust order intake, and margin-accretive acquisitions. Life Science and energy sectors led segment performance, while a strong acquisition pipeline and financial position support a cautiously optimistic outlook for H2 2026.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.